Simulations Plus (SLP) Set to Post Earnings on Thursday

Simulations Plus (NASDAQ:SLP) is anticipated to announce its Q4 2026 results after the market closes on Thursday, October 29th. Analysts expect Simulations Plus to post earnings of $0.09 per share and revenue of $17.44 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2026 earnings overview page for the latest details on the call scheduled for Friday, October 30, 2026 at 4:00 PM ET.

Simulations Plus Price Performance

Shares of SLP opened at $18.50 on Thursday. The firm has a market cap of $374.16 million, a P/E ratio of 46.25 and a beta of 1.31. The company has a 50 day simple moving average of $18.44 and a two-hundred day simple moving average of $17.14. Simulations Plus has a 1 year low of $11.09 and a 1 year high of $21.01.

Analyst Ratings Changes

A number of research analysts have recently weighed in on SLP shares. Weiss Ratings restated a “sell (d+)” rating on shares of Simulations Plus in a research report on Tuesday, October 6th. BTIG Research reiterated a “neutral” rating on shares of Simulations Plus in a research report on Wednesday, October 7th. Seven research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average target price of $17.25.

Simulations Plus Company Profile

Simulations Plus, Inc develops software and provides services that support pharmaceutical research, drug development and regulatory decision-making. Its technologies help scientists model how drug compounds behave in the body, assess formulation and delivery characteristics, and evaluate potential safety and efficacy outcomes.

The company’s software portfolio includes GastroPlus, a platform for physiologically based pharmacokinetic and pharmacodynamic modeling; ADMET Predictor, which forecasts absorption, distribution, metabolism, excretion and toxicity properties; and DDDPlus, which simulates drug dissolution and dosage-form performance.